PubMed Health⌕ Search

Biomedical subjects

M D Leslie

Publications and source records attributed to M D Leslie.

At least 19 recordsLinked to original sources
PubMed2004

The role of positron emission tomography in the management of colorectal cancer.

Positron emission tomography (PET) is a functional imaging modality that has made the transition from the research environment to the clinical environment over the last 10 years. Its major role is in the field of oncology where it is being used increasingly in the management of several tumour types including colorectal cancer. This review aims to outline the current and future role of PET scanning in the field of colorectal cancer.

Colorectal Neoplasms↗
PubMed2003

Peri-operative radiotherapy for rectal cancer: the case for a selective pre-operative approach - the third way.

Peri-operative radiotherapy has been used widely in addition to surgery in an attempt to reduce local recurrence (LR) following surgical resection of rectal cancer. Currently different groups follow different approaches with some routinely administering one weeks pre-operative radiotherapy to all cases of operable mobile cancer with others favouring postoperative chemoradiotherapy for selected high risk groups. In this review we bring together the changes in surgery, pathology and imaging that have occurred in recent years and together with the data from recent randomized pre-operative radiotherapy trials propose a logical and optimal way of managing rectal cancer. This third way is selective and pre-operative and should ensure a low rate of LR with radiotherapy reserved for those cases that need it.

Algorithms↗
PubMed2002

Successful chemoradiotherapy for anal cancer despite previous radical radiotherapy for gynaecological malignancy.

Repeat radical irradiation of the pelvis is generally not undertaken because of concerns regarding normal tissue damage; in particular to small bowel, bladder and bone. Two patients with carcinoma of the anal canal are presented who had previously been treated by radical pelvic radiotherapy for gynaecological malignancy. Both were re-treated with radical radiotherapy to the pelvis with concomitant chemotherapy. A complete remission of anal cancer was achieved in both patients with minimal acute and late toxicities.

Adult↗
PubMed2001

Management of Merkel cell carcinoma.

Merkel cell carcinoma is an uncommon cutaneous malignancy. Although it is rare, Merkel cell carcinoma has been described as the most malignant primary skin tumor. It is therefore important that once diagnosed, Merkel cell carcinoma is treated appropriately. The aim of this short review is to provide a summary of the available literature to guide clinicians in the future management of such patients. Inevitably in such a rare disease, there are no randomized trials of therapy. The treatment of individual patients will rely on opinion as much as the 'evidence'.

Carcinoma, Merkel Cell↗
PubMed2000

Fluorodeoxyglucose PET in the initial staging of germ cell tumours.

Testicular cancer is a rare tumour with the potential for cure at diagnosis. It is important, however, to identify those patients with metastases at presentation so as to ensure that the optimum treatment strategy is employed. Many criteria have been used to try to place patients into high- or low-risk groups, with variable success. Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has the potential to identify active disease and thereby influence further management. Here we report on a retrospective study of the use of FDG-PET in the detection of metastatic testicular carcinoma at diagnosis. Thirty-one patients [13 with seminoma and 18 with non-seminomatous germ cell tumours (13 teratomas, 5 mixed)] were staged by FDG-PET scanning. The imaging was performed using a Siemens ECAT 951 scanner. All results were assessed on the basis of histology or clinical follow-up. FDG-PET scan identified metastatic disease in ten and was negative in 16; there were no false-positives and five false-negatives. There were six patients in whom FDG-PET was negative and computed tomography was regarded as suspicious but follow-up was inconclusive. The positive predictive value was 100%. The negative predictive value was 76% or 91%, depending on whether the aforementioned six cases were regarded as true-negatives or false-negatives. It may be concluded that FDG-PET is capable of detecting metastatic disease at diagnosis that is not identified by other imaging techniques. These preliminary results are sufficient to suggest that a large prospective study should be performed to evaluate the role of FDG-PET in primary staging of disease.

Adolescent↗
PubMed2000

Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.

Differentiation of active disease from fibrosis/mature teratoma in patients with residual masses or identifying of sites of recurrence in patients with raised markers following treatment of their testicular cancer remains a problem.(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) has the potential to identify active disease and thereby influence further management in these patients. We performed a retrospective study of the use of FDG-PET in detecting residual/recurrent testicular carcinoma in 55 patients (seventy FDG-PET scans). Forty-seven scans were for the assessment of residual masses (18 had raised markers) and 23 scans were for the investigation of raised markers in the presence of normal CT scans. True positive results were based on positive histology or clinical follow-up. FDG-PET had a positive predictive value (PPV) of 96% and a negative predictive value (NPV) of 90% in patients with residual masses. This PPV was equivalent to that of markers (94%) but FDG-PET had the advantage of identifying the site of that recurrence. The NPV was higher than that of markers. In patients with raised markers alone the PPV of FDG-PET was 92% but the NPV was only 50%. However, subsequent FDG-PET imaging was frequently the first imaging modality to identify the site of disease. FDG-PET effected a management change in 57% of cases. FDG-PET scanning detected viable tumour in residual masses and identified sites of disease in suspected recurrence.

Adolescent↗
PubMed1996

Gestational choriocarcinoma metastatic to the brain treated successfully by stereotactic radiosurgery and chemotherapy.

Metastatic gestational choriocarcinoma not uncommonly affects the central nervous system. If possible, the initial management of these metastases is surgical excision prior to chemotherapy, since these lesions are haemorrhagic. We report a patient with choriocarcinoma metastatic to the brain in whom surgery was potentially hazardous. Treatment was successfully given with stereotactic radiosurgery followed by chemotherapy.

Adult↗
PubMed1996

Palliation of symptomatic adrenal gland metastases by radiotherapy.

Whilst adrenal metastases are common in patients with metastatic disease, they are rarely symptomatic. We present a series of seven patients with painful adrenal metastases who were seen in one centre over an 18-month period. All responded to palliative radiotherapy with a reduction in pain.

Adrenal Gland Neoplasms↗
PubMed1995

An audit of the use of agreed treatment protocols at a major centre for cancer treatment.

The treatment that a patient with cancer receives may vary considerably, depending on where and by whom the treatment is given. Agreement on treatment protocols for patients undergoing cancer treatment is clearly a desirable aim. Within departments this will result in greater uniformity of treatment, lead to greater safety, facilitate the evaluation of treatment strategies, and improve cost effectiveness. We have examined prospectively the extent to which treatment protocols are being adhered to within a major cancer treatment centre. One hundred newly registered cancer patients were studied. The results are encouraging, with complete adherence to protocol for 84. Of the 16 occurrences of deviation from a protocol this was unavoidable for three and of minor importance for five, being relatively small changes in radiotherapy dose reflecting particular clinical situations. Thus, eight deviations represented serious departures from the protocols by the responsible clinicians. This study has shown that in a major cancer treatment centre the development of agreed treatment protocols is both feasible and practical.

Adult↗
PubMed1995

Iodine seeds in the treatment of slowly proliferating tumours in the head and neck region.

Locally recurrent/persistent disease is a major cause of morbidity and mortality in patients suffering from tumours arising in the head and neck region. Iodine-125, with its long half-life of 60 days, is particularly suited for the treatment of slowly proliferating tumours (e.g. adenoidcystic carcinomas) of this site. We report our experience with 18 patients using iodine-125 seeds, placed at the time of surgery in patients with such tumours. Eleven of the patients were treated for recurrent disease following previous radical treatment. Disease free survival was 89% at 2 years and 53% at 5 years after treatment. These results are encouraging in a group of patients in whom achieving and maintaining local control can be extremely difficult.

Adult↗
PubMed1994

The early changes in salivary gland function during and after radiotherapy given for head and neck cancer.

The salivary gland function of 47 patients treated by radical radiotherapy (CHART or conventionally fractionated treatment) for head and neck cancer has been studied before, during and for up to 12 weeks from the start of treatment. Pronounced falls in salivary flow and pH are seen once radiotherapy has commenced, particularly when both parotid glands are included in the treatment volume. The initial rate of reduction in flow reflects the rate of delivery of treatment. The parotid glands show the greatest sensitivity to radiotherapy compared with the other salivary glands and reduction in salivary flow is dependent on both dose and the proportion of the gland included in the treatment volume. These early changes in salivary gland function are as marked for patients receiving either CHART or conventionally fractionated treatment, so differing from the late changes which have been shown to be less evident after CHART.

Female↗
PubMed1993

Pneumothorax as a complication of tumour response to chemotherapy.

A patient with extensive pulmonary involvement by disseminated adenocarcinoma is presented. Response to chemotherapy resulted in the direct rupture of necrotic tumour tissue into the pleural cavity leading to a pneumothorax. The condition failed to improve with chest drainage and suction, necessitating surgical intervention. The development of the pneumothorax proved to be a fatal complication of treatment.

Adenocarcinoma↗
PubMed1993

Weekly cisplatinum concomitant with radical radiotherapy in the treatment of advanced head and neck cancer.

A total of 36 patients with advanced head and neck cancer were treated with radical radiotherapy and weekly concomitant cisplatinum chemotherapy. Rapid tumour response of both primary tumours and nodes was notable and an initial complete response rate of 75% was obtained. The disease free survival was 64% at 1 year and 52% at 2 years. The protocol proved feasible with little increase in toxicity from the addition of chemotherapy. Considering the advanced stage of the tumours treated the initial results are promising and this approach would seem to warrant further investigation.

Adult↗
PubMed1993

Impaired salivary gland function after radiotherapy compounded by commonly prescribed medications.

Impaired salivary gland function can be a major cause of late morbidity following the treatment of head and neck cancer with radiotherapy. A large number of commonly prescribed medications can also reduce salivary gland function. We report three patients with already impaired salivary gland function following successful radiotherapy in whom additional prescribed medication led to an increased reduction in salivary flow, thus further impairing the quality of life of these patients. Stopping the medication resulted in subjective and objective improvement in salivary gland function.

Aged↗
PubMed1992

Changes in serum and salivary amylase during radiotherapy for head and neck cancer: a comparison of conventionally fractionated radiotherapy with CHART.

The changes in serum amylase that occur when radiotherapy is given in the treatment of head and neck cancer has been studied in 41 patients, 29 treated by CHART and 12 by conventionally fractionated radiotherapy. The peak rise in serum amylase following the start of treatment is seen earlier and is greater in the patients receiving continuous hyperfractionated accelerated radiotherapy (CHART). The serum amylase returns to normal earlier in the CHART patients so that the area under the curve is the same for both groups. The difference probably reflects the more rapid delivery of treatment to the patients receiving CHART. A close correlation between the peak rise in serum amylase and the amount of parotid tissue in the treatment volume is demonstrated. For six patients the total amount of amylase secreted by the parotid gland during CHART was measured and found to decline rapidly within a few days of the start of radiotherapy. The rise in serum amylase that results from the irradiation of salivary tissue provides a unique biochemical measure of an early radiation effect in a normal tissue. This probably reflects the interphase cell death of serous salivary cells. Although these immediate changes are of considerable interest they may not relate to the late effects of radiation on salivary gland function.

Amylases↗